HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hillhouse Capital Related

510.938

-2.431-0.47%

Number of Gainers:13

Number of Losers:39

Number of Flat:3

PE:- -

High:514.365

Open:513.210

Low:502.011

Close:513.369

Loading ...

the Phase Iii Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

THOMSON REUTERS

BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate

BRIEF-Blue Moon Group Bids For Land Use Right Of A Land Parcel Situated In Guangzhou

Blue Moon Group - Bid for Land Use Right of a Land Parcel Situated in Guangzhou

THOMSON REUTERS

Blue Moon Group - Estimated Investment Amount in Project Is Not Less Than RMB890 Mln

THOMSON REUTERS

WuXi AppTec Offloads 4.23% Stake in WuXi XDC Cayman

MT Newswires Live

HBM Holdings' 2024 Profit Shrinks

MT Newswires Live

BRIEF-WuXi AppTec Announces Disposal Of Certain Share Assets In WuXi XDC

WuXi AppTec - Aggregate Realized Investment Gains From Disposal Is RMB1.847 Bln

THOMSON REUTERS

WuXi AppTec - Disposal of Certain Share Assets

THOMSON REUTERS

WuXi AppTec - Aggregate Transaction Amount Approximately HK$2.178 Bln

THOMSON REUTERS

WuXi AppTec - Continued to Dispose of 50.8 Mln Shares in WuXi XDC via Block Trade

THOMSON REUTERS

Peijia Medical Collaborates With Dsm-Firmenich to Create Groundbreaking Innovative Medical Device Products

THOMSON REUTERS

Tong Ren Tang's 2024 Profit Declines 12%

MT Newswires Live

Luye Pharma Group Rivastigmine Patch Approved for Alzheimer's Treatment in Japan

MT Newswires Live

BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer

MT Newswires Live

Poly Property's 2024 Profit Jumps Nearly 7%

MT Newswires Live

Luye Pharma - Rivastigmine Twice Weekly Transdermal Patch- Approved for Marketing in Japan

THOMSON REUTERS

Harbour Biomed Reports Full Year 2024 Financial Results

THOMSON REUTERS

Press Release: Harbour BioMed Reports Full Year 2024 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1583/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"Hillhouse Capital Related","latestPrice":510.9379,"timestamp":1743667695066,"preClose":513.36865,"halted":0,"volume":800075064,"delay":0,"changeRate":-0.004735,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-2.430756,"latestTime":"04-03 16:00:00","open":513.21,"high":514.3649,"low":502.0113,"amount":14527429687,"amplitude":0.024064,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743989400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1743643800000,1743652800000],[1743656400000,1743667200000]],"pbRate":2.40525,"peRate":23.782912,"turnoverRate":0.005639,"increases":14,"decrements":36,"flats":4,"marketCap":2843551999104,"floatMarketCap":2259017494144},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":514.3649,"amplitude":0.024064,"preClose":513.36865,"low":502.0113,"pbRate":"2.40525","latestPrice":510.9379,"volume":800075064,"delay":0,"open":513.21,"prevYearClose":446.93042,"prevWeekClose":512.397,"prevMonthClose":505.776,"prevQuarterClose":505.776,"fiveDayClose":514.452,"twentyDayClose":527.947,"sixtyDayClose":436.012,"secType":"PLATE","market":"HK","turnoverRate":0.005639,"peRate":23.782912,"marketCap":2843551999104,"floatMarketCap":2259017494144,"timestamp":1743667695066,"nameCN":"Hillhouse Capital Related"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":13,"down":39,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2525771311","title":"the Phase Iii Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2525771311","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525771311?lang=en_us&edition=fundamental","pubTime":"2025-04-05 22:17","pubTimestamp":1743862632,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250405:nTUA7MNXR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","02162","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2524723402","title":"BeiGene Scraps Ociperlimab Lung-Cancer Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2524723402","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524723402?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:34","pubTimestamp":1743676440,"startTime":"0","endTime":"0","summary":"BeiGene is ending development of its experimental lung-cancer treatment ociperlimab following the failure of a late-stage study.BeiGene on Thursday said it is stopping a Phase 3 trial of ociperlimab after the oncology company determined that the study was unlikely to meet its primary endpoint of overall survival.BeiGene in late 2021 inked an option, collaboration and license agreement for ociperlimab with Novartis that included an upfront payment of $300 million from the Swiss drugmaker.However, the companies in 2023 agreed to terminate the deal, with all rights to ociperlimab returning to BeiGene.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","BK1161","LU1969619763.USD","ONC","LU2328871848.SGD","BK1583","BK1588","LU0588546209.SGD","BK1500","BK4139","LU0307460666.USD"],"gpt_icon":0},{"id":"2524239130","title":"BRIEF-Blue Moon Group Bids For Land Use Right Of A Land Parcel Situated In Guangzhou","url":"https://stock-news.laohu8.com/highlight/detail?id=2524239130","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524239130?lang=en_us&edition=fundamental","pubTime":"2025-04-03 18:03","pubTimestamp":1743674594,"startTime":"0","endTime":"0","summary":"BRIEF-Blue Moon Group Bids For Land Use Right Of A Land Parcel Situated In GuangzhouApril 3  - Blue Moon Group Holdings Ltd 6993.HK:BID FOR LAND USE RIGHT OF A LAND PARCEL SITUATED IN GUANGZHOUESTIMATED INVESTMENT AMOUNT IN PROJECT IS NOT LESS THAN RMB890 MILLIONFurther company coverage: 6993.HK ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","06993","BK1102"],"gpt_icon":0},{"id":"2524877792","title":"Blue Moon Group -  Bid for Land Use Right of a Land Parcel Situated in Guangzhou","url":"https://stock-news.laohu8.com/highlight/detail?id=2524877792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524877792?lang=en_us&edition=fundamental","pubTime":"2025-04-03 17:00","pubTimestamp":1743670835,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1102","BK1583","06993"],"gpt_icon":0},{"id":"2524228777","title":"Blue Moon Group -  Estimated Investment Amount in Project Is Not Less Than RMB890 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2524228777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524228777?lang=en_us&edition=fundamental","pubTime":"2025-04-03 17:00","pubTimestamp":1743670835,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nFWN3QH0JG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1583","BK1102","06993"],"gpt_icon":0},{"id":"2524555469","title":"WuXi AppTec Offloads 4.23% Stake in WuXi XDC Cayman","url":"https://stock-news.laohu8.com/highlight/detail?id=2524555469","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524555469?lang=en_us&edition=fundamental","pubTime":"2025-04-02 19:11","pubTimestamp":1743592272,"startTime":"0","endTime":"0","summary":"WuXi AppTec  disposed of a further 50.8 million shares, equivalent to a 4.23% stake, in WuXi XDC Cayman  for around HK$2.18 billion on Tuesday, a Wednesday filing with the Hong Kong bourse said.The drug research and development company previously sold 86 million shares in the target company for roughly HK$2.43 billion on Nov. 8, 2024, and Jan. 10, 2025.The firm will use proceeds from the sale to accelerate the construction of global production capacity and capability, attract and retain outstanding talent, and strengthen its unique integrated CRDMO business model.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0216","LU0320764599.SGD","BK1583","LU1997245177.USD","BK1576","LU0708995583.HKD","LU1046422090.SGD","LU2125910500.SGD","LU2242644610.SGD","02268","LU0456842615.SGD","603259","02359","SG9999014674.SGD","LU0052750758.USD","LU2045819591.USD","LU1997245094.SGD","BK1141","LU2488822045.USD"],"gpt_icon":1},{"id":"2524251465","title":"HBM Holdings' 2024 Profit Shrinks","url":"https://stock-news.laohu8.com/highlight/detail?id=2524251465","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524251465?lang=en_us&edition=fundamental","pubTime":"2025-04-02 18:48","pubTimestamp":1743590934,"startTime":"0","endTime":"0","summary":"HBM's  profit plunged to $2.7 million in 2024 from $22.8 million in 2023.The drug company logged zero earnings per share during the year compared with $0.03 in the previous year, according to a Monday filing with the Hong Kong bourse.Revenue shrank to $38.1 million from $89.5 million a year earlier.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02142","BK1574","BK1161","BK1583"],"gpt_icon":0},{"id":"2524452940","title":"BRIEF-WuXi AppTec Announces Disposal Of Certain Share Assets In WuXi XDC","url":"https://stock-news.laohu8.com/highlight/detail?id=2524452940","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524452940?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:45","pubTimestamp":1743587114,"startTime":"0","endTime":"0","summary":"BRIEF-WuXi AppTec Announces Disposal Of Certain Share Assets In WuXi XDCApril 2  - WuXi AppTec Co Ltd 603259.SS:DISPOSAL OF CERTAIN SHARE ASSETSAGGREGATE TRANSACTION AMOUNT APPROXIMATELY HK$2.178 BILLIONCONTINUED TO DISPOSE OF 50.8 MILLION SHARES IN WUXI XDC VIA BLOCK TRADEAGGREGATE REALIZED INVESTMENT GAINS FROM DISPOSAL IS RMB1.847 BILLIONFurther company coverage: 603259.SS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF12P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","LU1046422090.SGD","LU2045819591.USD","LU0456842615.SGD","LU0052750758.USD","603259","LU1997245094.SGD","BK0216","BK1141","BK1583","LU2125910500.SGD","LU0320764599.SGD","BK1576","LU0708995583.HKD","LU2242644610.SGD","LU1997245177.USD","02359"],"gpt_icon":0},{"id":"2524820452","title":"WuXi AppTec - Aggregate Realized Investment Gains From Disposal Is RMB1.847 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2524820452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524820452?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:41","pubTimestamp":1743586890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF12P:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02359","603259","LU0320764599.SGD","BK1583","LU0456842615.SGD","LU2488822045.USD","LU1997245177.USD","BK1141","LU1997245094.SGD","LU2045819591.USD","LU1046422090.SGD","BK1576","LU2125910500.SGD","BK0216","LU0052750758.USD","LU0708995583.HKD","LU2242644610.SGD"],"gpt_icon":0},{"id":"2524528784","title":"WuXi AppTec -  Disposal of Certain Share Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2524528784","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524528784?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:41","pubTimestamp":1743586890,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF12P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0052750758.USD","LU0456842615.SGD","LU2045819591.USD","BK1576","LU2125910500.SGD","LU0708995583.HKD","LU1046422090.SGD","BK1141","LU1997245094.SGD","LU2242644610.SGD","LU1997245177.USD","LU0320764599.SGD","BK0216","BK1583","02359","LU2488822045.USD","603259"],"gpt_icon":0},{"id":"2524452873","title":"WuXi AppTec -  Aggregate Transaction Amount Approximately HK$2.178 Bln","url":"https://stock-news.laohu8.com/highlight/detail?id=2524452873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524452873?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:41","pubTimestamp":1743586890,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF12P:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0216","LU0708995583.HKD","603259","LU1046422090.SGD","LU2045819591.USD","LU2488822045.USD","BK1583","LU0052750758.USD","LU1997245094.SGD","LU2125910500.SGD","LU1997245177.USD","LU2242644610.SGD","LU0320764599.SGD","LU0456842615.SGD","BK1576","BK1141","02359"],"gpt_icon":0},{"id":"2524452827","title":"WuXi AppTec - Continued to Dispose of 50.8 Mln Shares in WuXi XDC via Block Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2524452827","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524452827?lang=en_us&edition=fundamental","pubTime":"2025-04-02 17:41","pubTimestamp":1743586890,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QF12P:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0708995583.HKD","BK1576","LU1997245177.USD","LU0052750758.USD","LU0456842615.SGD","BK1141","LU2045819591.USD","LU1997245094.SGD","LU1046422090.SGD","02359","BK0216","LU2488822045.USD","LU2125910500.SGD","LU2242644610.SGD","LU0320764599.SGD","603259","BK1583"],"gpt_icon":0},{"id":"2524904761","title":"Peijia Medical Collaborates With Dsm-Firmenich to Create Groundbreaking Innovative Medical Device Products","url":"https://stock-news.laohu8.com/highlight/detail?id=2524904761","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524904761?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:00","pubTimestamp":1743508808,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250401:nTUA5NTN9Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1583","09996","BK1100"],"gpt_icon":0},{"id":"2524165780","title":"Tong Ren Tang's 2024 Profit Declines 12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2524165780","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524165780?lang=en_us&edition=fundamental","pubTime":"2025-04-01 16:49","pubTimestamp":1743497392,"startTime":"0","endTime":"0","summary":"Tong Ren Tang Technologies'  attributable profit fell 12% to 521.8 million yuan in 2024 from 590.2 million yuan in 2023, according to a Friday filing with the Hong Kong bourse.Earnings per share at the traditional Chinese medicine company decreased to 0.41 yuan from 0.46 yuan in the previous year.Revenue grew 7.2% to 7.26 billion yuan from 6.77 billion yuan a year earlier.The company declared a final dividend of 0.18 yuan per share, similar to last year's dividend. The dividend will be paid on Aug. 11.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1515","BK1583","BK1191","BK1606","01666"],"gpt_icon":0},{"id":"2524156338","title":"Luye Pharma Group Rivastigmine Patch Approved for Alzheimer's Treatment in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2524156338","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524156338?lang=en_us&edition=fundamental","pubTime":"2025-04-01 15:01","pubTimestamp":1743490909,"startTime":"0","endTime":"0","summary":"Luye Pharma Group (HKG:2186) received approval from Japan's Ministry of Health, Labour and Welfare for its Rivastigmine twice weekly transdermal patch, according to a Monday filing with the Hong Kong ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1583","BK1606","02186","BK1191"],"gpt_icon":0},{"id":"2523486309","title":"BeiGene Says EMA Panel Recommends Approval of Tevimbra for Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2523486309","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523486309?lang=en_us&edition=fundamental","pubTime":"2025-03-31 19:32","pubTimestamp":1743420770,"startTime":"0","endTime":"0","summary":"BeiGene (ONC) said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Tevimbra combined with etoposide and platinum chemotherapy as a fi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1500","06160","BK1588","LU2328871848.SGD","BK1161","BK4139","LU0307460666.USD","ONC","LU0588546209.SGD","LU1969619763.USD","BK1583"],"gpt_icon":0},{"id":"2523912951","title":"Poly Property's 2024 Profit Jumps Nearly 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523912951","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523912951?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:57","pubTimestamp":1743418672,"startTime":"0","endTime":"0","summary":"Poly Property Services  attributable profit rose 6.8% to 1.47 billion yuan in 2024 from 1.38 billion yuan in 2023, according to a Monday filing with the Hong Kong bourse.Earnings per share at the property manager increased 7.1% to 2.683 yuan from 2.505 yuan in the previous year.Revenue grew 8.5% to 16.3 billion yuan from 15.1 billion yuan a year earlier.The company declared a final dividend of 1.332 yuan per share, payable July 25.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1258","BK1542","CFA.SI","LU0348767384.USD","BK1229","LU0348766576.USD","BK1589","BK1583","06049","LU0082770016.USD"],"gpt_icon":0},{"id":"2523914154","title":"Luye Pharma -  Rivastigmine Twice Weekly Transdermal Patch- Approved for Marketing in Japan","url":"https://stock-news.laohu8.com/highlight/detail?id=2523914154","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523914154?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:47","pubTimestamp":1743418029,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QC02N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1606","02186","BK1583","BK1191"],"gpt_icon":0},{"id":"2523879919","title":"Harbour Biomed Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523879919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523879919?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743416021,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nTUA5CH63Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2523191987","title":"Press Release: Harbour BioMed Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2523191987","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523191987?lang=en_us&edition=fundamental","pubTime":"2025-03-31 18:13","pubTimestamp":1743415980,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025. CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its financial results for the year ended December 31, 2024.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed,  commented: \"The year 2024 was a pivotal period for Harbour BioMed, marked by significant progress in research and development, strategic business expansion, and operational excellence. Despite a challenging macroeconomic environment, the Company demonstrated remarkable resilience, navigating inflationary pressures, global supply chain disruptions, and geopolitical uncertainties while remaining focused on its long-term growth objectives.Compared to 2023, the company's revenue sustainability has continued to improve. Annual recurring revenue in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","BK4555","BK4585","BK4588","02142","BK4099","03160","BK1161","BK1574","BK4232","SD","TSLP","BK4604","BK4022","TM","BK4213","R"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":138}]}}